Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.37 |
| ▸ | RET | P07949 | 5/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2405344 | 0.88 | DGAT1 (0.39) | DGAT1CHRM4HRH3MCHR1 | |
| SCHEMBL2411806 | 0.85 | TRPM8 (0.43) | DGAT1GPR119RETCHRM4HRH3 | |
| SCHEMBL2408002 | 0.84 | TRPM8 (0.41) | DGAT1GPR119RETCHRM4HRH3 | |
| SCHEMBL2406147 | 0.82 | AOC3 (0.38) | DGAT1 | |
| SCHEMBL2405723 | 0.81 | FFAR4 (0.41) | ACACBCNR1 | |
| SCHEMBL2406949 | 0.80 | CNR1 (0.39) | CHRM4HRH3MCHR1CNR1 | |
| SCHEMBL2408149 | 0.79 | FFAR1 (0.37) | DGAT1GPR119 | |
| SCHEMBL2404241 | 0.77 | HTR1A (0.37) | DGAT1HRH3MCHR1 | |
| SCHEMBL2406729 | 0.76 | MCHR1 (0.39) | DGAT1CHRM4MCHR1 | |
| SCHEMBL2404239 | 0.76 | CKS1B (0.41) | DGAT1CHRM4HRH3MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912218-B2 | Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-12-16 | — | — | US | disclosed |
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MET, ALK, REL | DGAT1 4017/4885GPR119 1017/4885RET 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.